AI may allow safer breast MRIs with lower contrast doses
NCT ID NCT04340180
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tested whether artificial intelligence (AI) can help doctors accurately identify breast tumors on MRIs that use a lower dose of gadolinium contrast dye. Reducing the dose may lower the amount of gadolinium deposited in the brain. The study included 20 women—half with breast cancer and half with benign findings—and compared low-dose images to standard-dose images using AI assistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST BENIGN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Kirklin Clinic
Birmingham, Alabama, 35249, United States